PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar ...

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic times, as the company's coronavirus treatment and vaccine generated enormous ...

Amazon's $4B stake in Anthropic and deep AWS integration boost enterprise AI adoption. Click here to find out how Claude ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR ...

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...